316810-82-9

Usage

Uses

Used in Chemical Reactions:
5-Bromo-7-Nitro-1H-Indazole is used as a reactant in various chemical reactions for its inhibitory properties, which are attributed to the presence of bromo and nitro groups in its structure.
Used in Pharmaceutical Production:
5-Bromo-7-Nitro-1H-Indazole is used as a constituent in the production of pharmaceuticals, where its reactivity and binding ability with other compounds play a crucial role in the synthesis of the final product.
Used in Fluorogenic Probe Preparation:
5-Bromo-7-Nitro-1H-Indazole is used as a component in the preparation of fluorogenic probes, which are essential tools in chemical biology research and other scientific applications.
Used in Bioconjugation Applications:
5-Bromo-7-Nitro-1H-Indazole is used in bioconjugation applications, where its reactivity allows for the attachment of biological molecules to other compounds, facilitating the development of new diagnostic and therapeutic tools.
Used in Chemical Biology Research:
5-Bromo-7-Nitro-1H-Indazole is used as a research compound in chemical biology, where its properties and interactions with other molecules are studied to gain insights into various biological processes and the development of new chemical entities.

Upstream product

• 77811-44-0 4-bromo-2-methyl-6-nitroaniline 
• 570-24-1 2-Methyl-6-nitroaniline 

Downstream Products

• 316810-86-3 5-bromo-1H-indazol-7-amine 

Relevant academic research and scientific papers

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Indazole compounds and application thereof to preparation of IDO inhibitors

The invention discloses indazole compounds as shown in a formula (i) or (II) which is described in the specification, and a preparation method thereof, and application of the compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections related to cellular immune activation,autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

Indazole compounds containing nitrogen substituents, and application of same as IDO inhibitors

The invention discloses nitrogen substituent-containing indazole compounds as shown in a formula (I) which is described in the specification, a preparation method for the compounds, and application ofthe compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections relatedto cellular immune activation, autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

Polysubstituted-indazole compounds and application of same as IDO inhibitors

The invention discloses polysubstituted-indazole compounds as shown in a formula (I) which is described in the specification, a preparation method for the compounds, and application of the compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections related to cellular immune activation, autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

Discovery of a novel series of N-phenylindoline-5-sulfonamide derivatives as potent, selective, and orally bioavailable Acyl CoA:monoacylglycerol acyltransferase-2 inhibitors

Acyl CoA:monoacylglycerol acyltransferase-2 (MGAT2) has attracted interest as a novel target for the treatment of obesity and metabolic diseases. Starting from N-phenylbenzenesulfonamide derivative 1 with moderate potency for MGAT2 inhibition, we explored

Research in 7-aminoindazole series: Synthesis of new halo-7H-4-methylpyrazolo[1,5,4-ef][1,5]benzodiazepin-6-ones and 5H-9-halo-6-methylpyrazolo[1,5,4-ef][1,5]benzodiazepin-4-ones

A new class of 7-aminohaloindazoles has been synthesized. Reactivity of the amino groups of these bicyclic systems has been investigated. The halogenated pyrazolo-1,5-benzodiazepinones have been synthesized by the condensation of 7-aminoindazoles with ethyl acetoacetate.